'Positive' Signs Abound For Perrigo, But 'Uncertainty' From Pandemic Complicates Outlook

"With all the positive things, I'd normally be raising guidance right now," says CEO Murray Kessler as Perrigo reports first-quarter results. But manufacturing operations aren't normal, and neither is the consumer health product marketplace.

"Uncertainty Ahead” sign on a background of blue sky with clouds

Perrigo Co. PLC would have an outlook that couldn't be better if it wasn't for the uncertainty the COVID-19 pandemic imposes on manufacturing and the marketplace.

The OTC private label and store brand giant, with presence also in the infant formula, branded nutritional product and generic...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Earnings

Kenvue Makes CEO Change Months After Critical Activist Investor Made Proxy Play For Board Seat

Thibaut Mongon is out as Kenvue CEO, a post he’s held since J&J spun it out in July 2023, after the firm’s results came under increased investor scrutiny over the past year. The board appointed as interim CEO Kirk Perry, a board member since December who most recently headed technology, data and pre

Perrigo Combines Americas, International Leads Into Global Post In Latest Move To Boost Results

 

Roberto Khoury, Perrigo’s international lead for a year, moves to CCO while his counterpart for the Americas region appointed in September 2023, Catherine "Triona" Schmelter, is leaving with her post eliminated in the firm’s changes.

Acquisitions Help Spain’s Uriach Grow Sales By More Than 50%

 
• By 

European consumer health player Uriach records sales approaching €500m in 2024 after completing acquisitions which took the firm into new markets.

Stada Held Back By Weak Cough & Cold Season

 
• By 

While sales of seasonal products struggled during Q1, Stada pointed to the continuing strength of its underlying Consumer Healthcare portfolio.

More from Business

Private Label ‘Smart Imitation’ Of National Brands’ Packaging Not So Wise In US OTC Drug Sector

 

First Insight survey with 1,267 US consumers showed 44% are more likely to try a private label product “marketed as a dupe of a high-end product.” Providers of OTC drugs as well as other medical products in US would tread on thin regulatory ice with the practice.

Haleon Invests In State-Of-The-Art Oral Care R&D Facility In The UK

 
• By 

Haleon described the opening of a new oral care R&D facility in the UK as a “major investment reflecting our commitment to advancing science and innovation.”

Over The Counter: How To Balance Access And Equity In Self-Care, With Bayer’s Emese Csoke

HBW Insight speaks to Bayer Consumer Health's global strategy director for regulatory, medical, safety, quality, and compliance Emese Csoke about how least how widening access to self-care solutions can be balanced with equity with regards to affordability.